Anti-EGFRvIII TandAbs recruiting either T- or NK-cells as bispecific therapeutic antibody candidates for the treatment of EGFRvIII plus tumors.
- Resource Type
- Journal
- Source
JOURNAL OF CLINICAL ONCOLOGY ; MAY 20 2016, 34 15, 2p. Supplement: S- Subject
- Language
- English
- ISSN
- 15277755